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Abstract 
Platelet-derived growth factor (PDGF) B-chain mRNA is readily detectable in malignant mesothelioma (MM) cell lines, but not in 
normal mesothelial (NM) cell lines. The high affinity receptor for PDGF B-chain dimers, the PDGF/3-receptor, is expressed in MM cell 
lines. NM cell lines predominantly express the PDGF a-receptor. Coexpression of the PDGF/3-receptor and its ligand may lead to an 
autocrine growth stimulating loop in the malignant cell type. In nuclear un off experiments, PDGF B-chain mRNA was detectable in 
MM cells only, indicating an increased level of transcription in this cell type. The proximal promoter of the PDGF B-chain gene contains 
DNaseI hypersensitive (DH) sites and mediates reporter gene activation in both normal and malignant cells. Nuclear proteins, extracted 
from both cell types, interact with DNA sequences within the proximal promoter around bp -64  to -61 relative to the transcription start 
site. Electrophoretic mobility shift assays (EMSAs) indicate that these factors are more abundantly present in the malignant than in the 
normal cell type. A DH site around -9.9 kb was found in both cell types. When tested in CAT assays, this region exerted a stimulatory 
effect on transcription i malignant cells. The elevated level of transcription of the PDGF B-chain gene in malignant cells may well be the 
result of interaction of regulatory sites in the proximal promoter and an enhancing element located at - 9.9 kb from the transcription start 
site. 
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1. Introduction 
Platelet-derived growth factor (PDGF) is a potent mito- 
gen and chemoattractant for cells of mesenchymal origin. 
It is composed of two subunit polypeptides: the A- and the 
B-chains. Homodimeric (AA and BB) as well as het- 
erodimeric (AB) forms of PDGF can be formed [18,19,40]. 
The polypeptides are encoded by distinct genes, which 
show a high level of structural similarity [2]. The PDGF 
B-chain is encoded by the c-sis protooncogene [48]. The 
three isoforms of PDGF (AA, AB, and BB) interact with 
Abbreviations: CAT, chloramphenicol acetyl transferase; CHX, cyclo- 
heximide; DH, DNaseI hypersensitive; EGF, epidermal growth factor; 
EMSA, electrophoretic mobility shift assay; HC, hydrocortisone; MM, 
malignant mesothelioma; NM, normal mesothelium; PDGF, platelet-de- 
rived growth factor 
* Corresponding author. Fax: + 31 10 4367601. 
cell surface receptors, which function as noncovalent 
dimers. The a-receptor subunit binds all three isoforms of 
PDGF with equal affinity, whereas the /3 subunit binds 
just the B-chain with high affinity [4,5,20,38]. 
Based on expression of PDGF chains and receptors in 
platelets, endothelial cells, smooth muscle cells and pla- 
cental trophoblasts, PDGF is thought o function in wound 
healing and developmental processes among others [34]. In 
addition, the PDGF A- and B-chain genes have been 
shown to be expressed, either individually or together, in 
various tumors, like malignant mesothelioma (MM), and 
tumor derived cell lines [28,30,33,49]. MM is a tumor of 
mesodermal origin most often found in the pleura [47]. Our 
MM cell lines express PDGF B-chain mRNA, while nor- 
mal mesothelial (NM) cells do not express this protoonco- 
gene [26,45]. Also, most MM cell lines express PDGF 
/3-receptor transcripts, while NM cells predominantly ex- 
press PDGF a-receptor mRNA [46]. Immunofluorescence 
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staining with antibodies directed against PDGF and the 
PDGF receptors of normal and malignant cells originating 
from either cell lines or primary material, largely con- 
firmed the mRNA expression pattern [27]. Taken together, 
these findings are suggestive of an autocrine growth stimu- 
lating loop existent in malignant mesothelioma. Direct 
evidence for the autocrine growth stimulating potential of 
PDGF comes from studies with astrocytoma and glioblas- 
toma cell lines in which dominant-negative PDGF mutants 
and PDGF neutralizing antibodies were shown to revert 
the transformed phenotype of the cell lines [39,43]. 
The elevated level of PDGF B-chain mRNA in MM cell 
lines prompted us to study the regulation of expression of 
this protooncogene. Recently, proximal promoter elements 
of the PDGF B-chain gene [21,22,24,25,31] as well as 
several regions containing regulatory elements outside the 
minimal promoter region have been identified in other cell 
types [6,7,11]. We demonstrate hat the elevated level of 
PDGF B-chain expression in MM cells is caused by 
enhanced transcription. Enhanced binding of nuclear fac- 
toffs) to sequences around bp -64  to -60  bp in MM 
cells may contribute to this elevated expression, as well as 
a DNaseI hypersensitive site at -9.9 kb, which exerts a 
stimulatory effect on transcription. 
2. Materials and methods 
2.1. Cell lines and growth conditions 
Experiments were performed using human MM cell 
lines (Mero-25, -41 and -82) and NM cell lines (NM-5, -20 
and -21) [45]. All cell lines were cultured in Ham's F10 
medium (Gibco/BRL, Life Technologies, Paisley, UK) 
with 15% fetal calf serum (FCS) under 5% CO 2 at 37°C. 
Epidermal growth factor (EGF; Collaborative Research, 
Lexington, MA, USA; 10 ng/ml) and hydrocortisone (HC; 
Sigma, St. Louis, MO, USA; 0.4 /xg/ml) were added to 
the culture medium of NM cells. In some experiments cells 
were exposed to cycloheximide (CHX; Sigma; 10 /xg/ml 
medium) for 2 h. 
2.2. Probes 
1.7 kb BamHI PDGF B-chain [16] and 0.7 kb EcoRI- 
PstI GAPDH [1] fragments were used as probes in North- 
ern blot analysis. Nuclear run off assays were performed 
with the 2.0 kb XhoI PDGF B-chain fragment from pSM1 
[23] and the 1.25 kb PstI fl-actin fragment from pAct [9]. 
Both these probes were subcloned in pUC18 and subse- 
quently spotted onto nitrocellulose filters prior to hy- 
bridization. Subcloned sequences ofhuman genomic PDGF 
B-chain clones were used for mapping of DH sites (see 
also Fig. 2). PR3 is the 0.61 kb SmaI-EcoRI fragment of 
pAO56, PR7 the 0.35 kb PstI-HindlII fragment of 
pAO121, PR12 the 0.9 kb HindlII-KpnI fragment of 
pAO56, PR13 the 0.46 kb SmaI-HindIII fragment of 
pAO149, and PR16 the 0.38 kb PstI-PvulI fragment of 
pAO121, pAO56, pAO149, and pAO78 contain 11 and 5 
kb EcoRI and 8 kb BamHI fragments of cosmid clone 
ALLW- 1283-C1 21, respectively. Cosmid ALLW- 1283-C1 
21, pAO68 and pAOI21 were described elsewhere [41,42]. 
DNA probes DHI-IWT ( -103/ -23) ,  DHI-IMUTA 
( -  103/ -  23), DHI-IWT-5' ( -  103/ -  54) and DH1- 
1WT-3' ( -73 / -  23) were used in electrophoretic mobil- 
ity shift assays (EMSAs). These probes were obtained by 
PCR with linker primers (BamHI or EcoRI) using cloned 
promoter sequences as templates. The amplified products 
were cloned into pUC 19 after restriction enzyme digestion 
and gelpurification. These constructs were checked by 
sequencing. DHI- 1MUTA is the mutant form of DH1- lWT 
in which the sequence -64  TCTC -61 has been changed 
into -65  ATATC -61 [8]. End-labeling of the probes 
was performed as described earlier [44]. Enzyme combina- 
tions were either BamHI/EcoRI or EcoRI/BamHI. 
2.3. Reporter gene constructs for CAT analysis 
pSV2CAT and pSuperCAT (a promoterless CAT con- 
struc0 were used as positive and negative controls for 
CAT analysis, respectively, pSis-1758/+43CAT, pSis- 
425/+ 43CAT, and pSis-112/+ 43CAT have been de- 
scribed by others [6,8]. pSis-425/+ 43CAT was used to 
construct unidirectional deletion mutants: pSis-65/+ 
43CAT, pSis-64/+43CAT, pSis-60/+43CAT, pSis- 
44 /+ 43CAT, and pSis-36/+ 43CAT, using exonuclease 
III (Promega, Madison, WI, USA) [8]. pS is - l l2 /+ 
18mutaCAT is a site-directed mutant form of pSis-112/+ 
18CAT in which the sequence -64  TCTC -61 has been 
changed into -65  ATATC -61 [8]. All these constructs 
were checked by sequencing. All other reporter constructs 
were made by subcloning PDGF B-chain genomic frag- 
ments in sense (s) or antisense (a) orientation in the 
SmaI-site, upstream of the PDGF B-chain promoter in 
pSisl(s)fAT (= pS is - l l2 /+ 43CAT) (Fig. 3, [6,7]). 
PDGF B-chain-CAT fusion constructs 2(s), 3(s), and 4(s) 
contain the 170 bp (+302 to +472) Hinfl-XhoI, 297 bp 
(+472 to +761) XhoI-BamHI, and 449 bp (+761 to 
+1210) BamHI-BstEII fragments of pAO121, respec- 
tively; 5(s) and 6(s) the 0.7 kb PstI and 3.4 kb KpnI 
fragments of pAO78, respectively; 10(s/a), 12(s/a), 13(s), 
and 14 (s/a) the 6 kb HindlII-BamHI, 0.6 kb BstUI, 0.7 
kb SstI-NarI, and 1.5 kb PzulI-BamHI fragments of 
pAO56, respectively. 
2.4. Northern and Southern blot analysis 
DNA isolation and Southern blot analysis (Hybond-N 
membranes, Amersham Int., Buckinghamshire, UK) were 
performed according to standard procedures. RNA isola- 
tion and Northern blotting were performed as described 
elsewhere [26]. 
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2.5. Nuclear run off assay 
Isolation of nuclei, in vitro labeling of nuclear RNA and 
hybridization protocol have been described elsewhere [26]. 
2.6. Mapping of DNaseI hypersensitive (DH) sites 
Mapping of DH sites was performed largely according 
to a previously described protocol [6]. Nuclei were isolated 
from either 6X 108 NM or 6X108 MM cells. After 
DNaseI (Gibco/BRL, Life Technologies, Paisley, UK) 
treatment and restriction enzyme (Pharmacia, Uppsala, 
Sweden) digestion, electrophoresis and blotting, hybridiza- 
tion (5 x SSPE, 0.1% SDS, 0.1% Ficoll, 0.1% BSA, 0.1% 
polyvinylpyrrolidone and 100/xg/ml salmon sperm DNA) 
was performed at 65°C, overnight. Filters were washed in 
1 X SSPE, 0.1% SDS at 65°C. Filters were exposed to 
Kodak X-OMAT film (Eastman Kodak Co., Rochester, 
NY, USA) with intensifying screens at -80°C. 
2.7. In vivo footprinting 
DMS treatment of subconfluent NM or MM cell cul- 
tures, DNA isolation and piperidine cleavage of in vitro or 
in vivo modified methylated guanine residues were all 
performed as described earlier [8]. Subsequently, genomic 
footprinting was performed by means of ligation-mediated 
PCR (LM-PCR) [12] using PDGF B-chain promoter- 
specific primer sets. PDGF B-chain primers ls (5'-CATG- 
GACTGAAGGGTTGCTC-3'; -190/ -171) ,  2s (5'- 
CTCTCAGAGACCCCCTAAGCGCCCC-3'; - 168/ -  
144), and 3s (5'-AGACCCCCTAAGCGCCCCGCC- 
CTGG-3'; - 161/ -  137) were used for lower strand anal- 
ysis. Primers la (5'-CGCAAAGTATCTCTATCTAGG- 
GAA-3' ;  + 131/+ 108), 2a (5 ' -TAGGGAAT-  
GAAAAATGGGCGCTGGC3'; + 114/+ 90), and 3a (5'- 
GGAATGAAAAATGGGCGCTGGCGGC-3'; + 111 / + 
86) were used for upper strand analysis. First strand syn- 
thesis (primers l s and la), PCR amplification (primers 2s 
and 2a), and labeling reactions ([y-32P]ATP-labeled 
primers 3s and 3a) were all performed as described, using 
Vent DNA polymerase (Thermococcus litoralis DNA 
polymerase; New England Biolabs, Beverly, MA, USA) 
[8]. Mixtures were separated on 6% polyacrylamide se- 
quencing els (Bio-Rad Laboratories, Hercules, CA, USA) 
in 1 X TBE (90 mM Tris, 90 mM Boric acid, 25 mM 
EDTA). Gels were dried and exposed to Kodak X-OMAT 
film (Eastman Kodak Co.) with intensifying screens at 
-80°C for 1 wk. 
2.8. Transfections and CAT assays 
1.8-2.0 x 10 6 NM or 1.8-2.0 X 10 6 MM cells were 
seeded in 10 cm-dishes and cultured in the appropriate 
culture medium at 37°C under 5% CO 2 for 24 h. Cells 
from subconfluent cultures were transfected with 1 /zg 
pCHI10 (/3-galactosidase expression vector; Phannacia) 
and 9 /zg reporter construct in combination with 30 /~g 
Lipofectin (Gibco/BRL, Life Technologies Ltd., Paisley, 
UK) in 3 ml serum-free OptiMEM culture medium 
(Gibco/BRL, Life Technologies Ltd., Paisley, UK) [10]. 
Two 10 cm-dishes with cells were used for each transfec- 
tion with reporter construct. After 16 h of culture, 3 ml 
culture medium containing 30% FCS (supplemented with 
EGF and HC for NM cells) were added, resulting in a final 
concentration of 15% FCS. All cells were harvested 48 h 
later and cell lysates were prepared [35]. /3-galactosidase 
activity was used as a means to correct for the variation in 
transfection efficiencies of the various reporter constructs. 
Amounts of protein corresponding to equal /3-galacto- 
sidase activity were used in CAT analysis [15]. After 1 h 
incubation at 37°C, an additional volume of 20 /xl 4 mM 
acetyl coenzyme A was added and the incubation was 
allowed to continue for another hour. Samples were ex- 
tracted with ethyl acetate and analyzed on silica gel TLC 
plates (J.T. Baker, Phillipsburg, NJ, USA). CAT activity 
was quantified by means of a PhosphorImager TM (Molecu- 
lar Dynamics, Sunnyvale, CA, USA). In each experiment, 
CAT activity of the promoterless pSuperCAT construct 
was subtracted from the values obtained for each construct. 
After correction, CAT activities were expressed as percent- 
age of the activity of a reference construct. Hence, the 
mean and standard deviation were calculated based on 
log-transformed values. 
2.9. Electrophoretic mobility shift assays (EMSAs) 
Nuclear extracts were prepared from either 2.5 X 10 6 
NM or 2.5 X 10 6 MM cells according to an earlier de- 
scribed method [37] with minor modifications [44]. Usu- 
ally, 2-4 /zl of nuclear extract contained 4 /xg protein as 
determined by the method of Bradford [3]. 
Standard EMSA reactions contained 4 /xg of nuclear 
extract in a final reaction volume of 20 /~1. In titration 
experiments, either 0.5, 1, 2 or 4/zg were used. Reaction 
mixtures contained: nuclear extract, 10 mM HEPES pH 
7.9, 60 mM KC1, 4% (v/v)  glycerol, 5 mM MgC12, 1 mM 
CaC12, 1 mM DTT, and non-specific, unlabeled competi- 
tor DNA (poly(dI:dC).(dI:dC) (Pharmacia)). The optimal 
poly(dI:dC).(dI:dC) concentration of 0.4 /xg per 20 /zl 
reaction volume was determined in titration experiments. 
After the addition of 1 /zl (7500 cpm//xl) labeled DNA, 
binding reactions were incubated on ice for 30 min. Reac- 
tions were separated on a 4% polyacrylamide g l (Bio-Rad 
laboratories, Hercules, CA, USA) in 0.25 X TBE (22.5 
mM Tris, 22.5 mM Boric acid, 6.25 mM EDTA) at 150 V 
for 1.5 h. Gels were fixed in 10% MeOH/ 10% glacial 
acetic acid for 15 min, dried on a slab gel dryer and 
exposed to Kodak X-OMAT film (Eastman Kodak Co.) 
with intensifying screens at -80°C overnight. 
To define the protein nature of the retarded bands, 
crude nuclear extracts were heated for 5 min at 90°C or 
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Fig. 1. Nuclear run off analysis. 32P-labeled nuclear RNA of NM-5 and 
Mero-25 were hybridized to nitrocellulose filters spotted with pUC18, 
pUC18 + actin insert, and pUC18 + PDGF B-chain insert. 
treated with 20 /zg of Proteinase K (Merck, Darmstadt, 
Germany) at 37°C for 15 min. 
In competition experiments with sequence specific or 
random probes, nuclear extracts were first incubated on ice 
for 10 min with either 0, 100 or 200 ng of unlabeled 
competitor DNA. Subsequently, 7500 cpm of labeled probe 
were added and the incubation allowed to proceed on ice 
for another 30 min. Reactions were separated as described 
above. 
3. Results 
3.2. Mapping of DH sites in the PDGF B-chain gene 
extended promoter 
DNase I hypersensitivity of a genomic DNA region is 
thought to correlate with accessibility of that region to 
trans-acting factors [17]. Nuclei from NM-5, Mero-25, and 
-82, were digested with DNaseI. Subsequently, genomic 
DNA was isolated and digested with EcoRI or HindlII. 
The positions of DH sites were determined after gel elec- 
trophoresis, blotting and probe hybridization (Figs. 2 and 
3). 
DH +0.4, +0.6, and + 1.0 were detected after hy- 
bridization of the 22 kb EcoRI and the 5.2 kb HindlI 
fragments with PR16 and PR7, respectively. These DH 
sites were present in both NM and MM cell lines. Two 
additional DH sites, DH + 1.9 and +4.0, were identified 
within the first intron of the PDGF B-chain gene in MM 
cell lines, only. The proximal promoter region was found 
to be DNase I hypersensitive in both NM and MM cell 
lines. No DH sites were detected in other intron and exon 
sequences or immediately upstream of the proximal pro- 
moter. 
Examination of the partly overlapping 9.2 kb EcoRI 
and 8.1 kb HindlII fragments with probes PR3 and 
PR13/PR12, respectively, resulted in the detection of DH 
sites far upstream from the transcription start site. DH sites 
-8 .6  and -9 .9  were found in both NM and MM cell 
lines. An additional DH site, DH -7.3,  could only be 
detected in Mero-25 and -82. 
3.1. Nuclear run off analysis 
Nuclear un off assays were performed to determine the 
levels of PDGF B-chain nuclear mRNA in NM and MM 
cell lines (Fig. 1). No nuclear PDGF B-chain mRNA was 
detectable in NM cells. Neither could PDGF B-chain 
mRNA be detected after culturing in the presence of the 
protein synthesis inhibitor cycloheximide (CHX). In con- 
trast, PDGF A-chain transcripts and transcripts of the 
constitutively transcribed /3-actin gene were readily de- 
tectable [26]. In the MM cell lines, nuclear PDGF B-chain 
transcripts were clearly present. 
3.3. Mapping of the proximal promoter area 
The PDGF B-chain gene proximal promoter region was 
analyzed by in vivo DMS footprinting. This technique 
allows the identification of sequences bound by protein 
factors. The guanine (G) residues -1  and -61  in the 
lower strand were found to be hypermethylated in Mero-25, 
-41, and -82, compared to the corresponding residues in in 
vitro DMS-treated naked mesothelial cell DNA (Fig. 4). 
No such hypermethylated r sidues were detectable in NM 
cells. 
1 2 7 
• • ..... 
-1'6 ' -42 ' -8 ' -~ ' ; ' ~, ' ; ' 2 'o '  2 ' . '  28 'kb 
PR3 PR 16 PR9 
E H E H E H H H E E 
I L I I I I I I . . . . .  I J 
PR12 PR13 PR7 
Fig. 2. Partial restriction map and probes used for mapping of DH sites in the extended promoter region of the PDGF B-chain gene. Exons are indicated as 
numbered boxes. Lower panel: numbered boxes indicate the position of genomic probes. E = EcoRI; H = HindIII. 
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Fig. 3. Localization of DH sites within, and upstream of the proximal promoter of the PDGF B-chain gene. Exons are indicated as numbered boxes. 
Arrows indicate DH sites. Fragment l (s/a)  corresponds tothe - 112/+ 43 'minimal' promoter area. Bars indicate fragments cloned in sense (s) and/or 
antisense (a) orientation 5' of the l(s) fragment in CAT reporter gene constructs. 
3.4. Functional analysis of the proximal promoter area 
The activity of the PDGF B-chain proximal promoter 
area in NM as well as MM cell lines was analyzed in 
transfection studies with chloramphenicol acetyl trans- 
ferase (CAT) reporter gene constructs. Comparable basal 
promoter activity was obtained with a 1758 bp fragment 
immediately upstream from the transcription start site in 
NM and MM cells. Most of the activity was retained when 
the 1758 bp fragment was narrowed own to 112 or even 
65 bp upstream of the transcription start site. The activity 
of the 112 bp fragment was much reduced when used in 
the antisense orientation. We tested the importance of the 
hypermethylated G-61 in a series of transfection experi- 
ments with deletion constructs ranging from bp -64  to bp 
-36 .  A reduction in activity was observed between bp 
-64  and -60  in the MM cell lines (Fig. 5A). The site 
directed mutant, - 112/+ 18mutaCAT ( -  65 ATATC 
-61  instead of -64  TCTC -61)  was constructed to 
analyze this sequence in more detail. In the MM cell lines, 
a significant reduction of activity was obtained with this 
construct (Fig. 5B). A similar, but not significant effect, 
was seen in NM cells (Fig. 5B). 
3.5. Electrophoretic mobility shift assays (EMSAs) 
EMSAs were used to analyze the binding of nuclear 
protein factors to the proximal promoter. DNA constructs, 
50 to 80 bp in length, were end-labeled and tested for their 
in vitro binding capacity of nuclear proteins. A bandshift 
pattern consisting of two major bands was obtained with 
to  
~, 6 6 
i . _  x_  
m m 
+ Z ~ + 
G-1  " 
TATA I 
G-60 - 
G-61 -u- 
- G-1 
- G -60  
-L_ G-61 
Fig. 4. In vivo footprint analysis of the human PDGF B-chain gene 
promoter. Cells were treated with DMS in vivo, DNA was cleaved by 
piperidine, and G residues were sequenced. Numbers indicate positions of 
G residues in the lower strand relative to the transcription i itiation site in 
NM-21, Mero-25, and Mero-41. + = in vitro treated naked DNA. 
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Mero-82 NM Mero-25 Mero-41 Mero-82 
Fig. 5. Relative CAT activities of NM and MM cell lines transfected with various PDGF B-chain gene promoter/CAT fusion constructs. CAT activities 
are expressed as percentage conversion after correction for the transfection efficiency. CAT activity from the promoterless pSuperCAT construct was 
subtracted from each value. Transfection efficiencies were determined by measuring /3-galactosidase activity obtained from the co-transfected xpression 
vector pCH110. Corrected activities are plotted on a logarithmic scale relative to pSis-64/+ 43CAT ( - 64; A) or pSis-112/+ 18CAT (wt; B), which have 
a set value of 1. The calculated means of data from 2-4 independent transfection experiments are plotted. SD are indicated by error bars. 
construct DHl - lWT( -103/ -  24) and nuclear extracts 
from both NM and MM cells. The formation of the 
bandshift pattern was inhibited after the nuclear extracts 
were treated with proteinase K or when incubated at 90°C 
for 5 min. indicating the protein nature of the factors. 
From titration experiments with increasing amounts of 
nuclear extract of either NM or MM cell lines, it becomes 
apparent, hat less MM nuclear extract is needed to gener- 
ate a bandshift pattern than NM nuclear extract (Fig. 6A). 
Also, higher amounts of unlabeled sequence specific com- 
petitor DNA were needed to inhibit the formation of the 
bandshift pattern of nuclear extracts from MM cells than to 
inhibit the bandshift pattern of nuclear extracts from NM 
cells (Fig. 6B). These data suggest, that the nuclear factors 
responsible for the bandshift are more abundantly present 
in MM than in NM cells. When DHI - IMUTA ( -65  
ATATC -61  instead of -64  TCTC -61)  was used, the 
in vitro binding potential of the construct was markedly 
reduced (Fig. 6A). The bandshift pattern of DH1- 
1WT( -103/ -24)  was retained when probe DHI- IWT-  
5 ' ( -103/ -54)  was used. Only the faster moving band 
was obtained with DHl - lWT-3 ' ( -73 / -23)  and nuclear 
extracts of both NM and MM cells (Fig. 6C). 
3.6. Functional analysis of other DH sites 
All other DH sites were analyzed for their ability to 
enhance or reduce basal PDGF B-chain gene promoter-in- 
duced CAT activity in NM and MM cells. To this end, 
CAT reporter gene constructs were prepared by cloning 
sequences representing DH sites upstream and downstream 
of the 112 bp B-chain 'minimal' promoter [ = construct 
l(s)] (Fig. 3). These constructs were transfected into the 
appropriate cell lines. 
DH sites, DH + 1.9 and + 4.0, could only be detected 
in MM cells. Construct 5s contained DH + 1.9 and con- 
struct 6s contained DH + 4.0. Neither of these constructs 
had an effect on the level of CAT activity. 
The integral activity of all DH sites in the - 12 / -  6 kb 
region was analyzed in transfection experiments with the 
10(s) and 10(a) constructs. These constructs induced a 
reduction of activity in NM cells (Fig. 7A). In MM cell 
lines, construct 10a induced no or a minor increase in basal 
activity (Fig. 7B and 7C). Construct 10s had no obvious 
effect in these cell lines. 
A minor silencing effect was obtained with the 12(s) 
fragment in NM cells (Fig. 7A). This fragment contains 
Fig. 6. EMSA experiments with nuclear extracts of MM or NM cell lines and end-labeled probes. Increasing amounts of nuclear extract of either NM-21 or 
Mero-25: 0.5, 1, 2, 4 /xg, were incubated with 7500 cpm of DHI-IWT or DHI-IMUTA (A). EMSA experiment with 4 p,g of nuclear extract of either 
NM-21 or Mero-25 and 7500 epm of DHI-IWT and either 0, 100 or 200 ng of unlabeled, specific competitor DNA (B). EMSA experiment with 4 gg of 
nuclear extract of either NM-21 or Mero-25 and 7500 cpm of either DHI-1WT, DHI-IWT-5' or DHI-lWT-3' (C). * indicate specifically retarded bands. 
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Fig. 7. Relative CAT activities of NM (A) and MM (B and C) cell lines transfected with various PDGF B-chain gene promoter/CAT fusion constructs. 
After correction for transfection efficiencies, CAT activities were determined aspercentage conversion. Transfection efficiencies were determined by
measuring fl-galactosidase activity obtained from the co-transfected expression vector pCH110. CAT activity of the promoterless pSuperCAT construct 
was subtracted from each value. Corrected activities are plotted on a logarithmic s ale relative to pSis-112/+ 43CAT [l(s)], which has a set value of 1. 
The calculated means of data from 2-4 independent transfection experiments are plotted. SD are indicated by error bars. ND, not determined. 
DH -9 .9  and exerts its silencing effect in both the sense 
(s) and antisense (a) orientation. In Mero-25, and -82, the 
12(a) construct resulted in a 2- to 3-fold enhancement of 
basal activity. The enhancing effect of the 12(s) fragment, 
however, could only be demonstrated in Mero-82 (Fig. 
7C). 
Neither in NM nor in MM cells did 13(s) and 14(s/a), 
which contain DH -8 .6  and DH -7 .3 ,  respectively, 
affect basal promoter activity. 
4. Discussion 
Earlier studies showed, that PDGF B-chain mRNA 
expression was clearly detectable in human MM cell lines, 
but not in NM cell lines [14,45]. The elevated PDGF 
B-chain expression in MM cell lines could not be at- 
tributed to rearrangements or amplifications of chromo- 
some 22 [45]. Therefore, nuclear run off experiments were 
conducted to investigate PDGF B-chain mRNA expression 
at the transcriptional level. Nuclear PDGF B-chain tran- 
scripts were detectable in MM cells, while no such tran- 
scripts were found in NM cells. PDGF A-chain transcripts, 
however, were readily detectable in these cell lines [26]. 
Even after CHX treatment no PDGF B-chain mRNA was 
detectable in NM cells. Hence, the inability to detect 
PDGF B-transcripts among total RNA of NM cells cannot 
be attributed to messenger instability. Similarly, in 
glioblastoma nd bladder carcinoma cell lines as well as in 
human umbilical vein endothelial cells CHX treatment did 
not affect the detection of transcripts [13,32]. In contrast, 
CHX clearly enhanced steady-state PDGF B-chain mRNA 
levels in TPA treated HL-60 cells and in resting and LPS- 
and TPA-treated human monocytes [29,36]. The PDGF 
B-chain mRNA half-life was determined in actinomycin 
D-treated MM cell lines (data not shown). Its value of 2 to 
3 h is similar to earlier reported half-lives in glioblastoma, 
bladder carcinoma, PC3, HeLa and TPA-treated K562 
ceils [2,32]. The elevated steady-state PDGF B-chain 
mRNA level in MM cell lines, therefore, can be attributed 
to an increased transcription rate. 
The extended promoter egion of the PDGF B-chain 
gene was studied to identify structures responsible for the 
elevated level of transcription in MM cells. The proximal 
promoter egion was found to be DNaseI hypersensitive in
NM as well as in MM cell lines. Moreover, the 1758 bp 
immediately upstream from the transcription start site could 
direct transcription of the CAT reporter gene in both cell 
types. Most of the activity was retained when the promoter 
area was narrowed down to -112  or -65  bp relative to 
the transcription start site [42]. A slight decrease in activity 
was detected when the promoter area was reduced by 
another five nucleotides. The elevated level of transcrip- 
tion in MM cells can not be explained by a mutational 
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event in the 'minimal' promoter area. Sequencing of bp 
- 393 to + 140 revealed a nucleotide sequence in MM cell 
lines identical to that in NM cell lines (data not shown). 
Site directed mutagenesis of the area between bp - 64 and 
-61 ,  however, resulted in a clear inhibition of transcrip- 
tional activity in MM cells. Only a minor inhibitory effect 
was observed in NM cells. Therefore, this area was ana- 
lyzed for its capacity to bind nuclear factors in EMSA 
experiments. Specific binding of nuclear factors to a 80 bp 
construct, DHI - IWT( -103/ -  24), was demonstrated in 
both MM and NM cells. However, the concentration of 
factors was higher in extracts from MM cells than in 
extracts from NM cells as demonstrated in competition 
experiments with unlabeled probe DNA and in titration 
experiments with increasing amounts of nuclear extract 
(Fig. 6A and B). The lower concentration of factors in the 
NM cells may explain the results of the footprint experi- 
ments, in which factors binding to this region could only 
be demonstrated in MM cells. In both cell types, binding 
in EMSA experiments was much reduced using a construct 
with the mutated sequence, DHl - lMUTA( -103/ -  24) 
(Fig. 6A). In undifferentiated K562 cells and HeLa cells, 
the - 64 / -  61 region is involved in activation of PDGF 
B-chain gene transcription [8]. Adjacent o this region the 
core binding site for the ubiquitously expressed transcrip- 
tion factor SP1 (CCACCC) is located at bp -61  to -56  
and an overlapping binding site for Egr-1, which interacts 
with SP1 in endothelial cells [24,25]. The bandshift pattern 
of DHI - IWT( -  103/ -  24) was retained when a 3'-trun- 
cated mutant, DHI - IWT-5 ' ( -  103/ -  54), was used. With 
the 5'-truncated mutant, DHl - lWT-3 ' ( -73 / -24)  only 
the faster moving band was obtained (Fig. 6C). These 
results can be explained through the interaction of nuclear 
factors with regulatory elements, which have been reported 
to be present in the 30 bp stretch from bp -100  to -70  
relative to the transcription start site [22,24,31]. From our 
experiments it is clear that there are no qualitative differ- 
ences between NM and MM cells in the binding capacity 
of nuclear factors to this region, but that rather quantitative 
differences discriminate MM from NM cells. Binding of 
factors, therefore, cannot explain the enhanced transcrip- 
tion of the PDGF B-chain gene in MM cells. Methylation 
of promoter sequences or inaccessibility of the promoter 
due to nucleosome phasing are not expected to play an 
important regulatory role either as determined by Southern 
blot analysis with methylation sensitive restriction en- 
zymes (data not shown) and by mapping of DNaseI hyper- 
sensitive sites. 
DH sites were also found in other regions of the PDGF 
B-chain promoter. No enhancing nor repressing effects on 
transcription were exerted by DH -8 .6  or DH -7.3.  
Neither was transactivating potential detectable for first 
exon and first intron sequences in MM cell lines (data not 
shown). This is in agreement with other reports on cervix 
and prostate carcinoma cell lines [6,7]. A transcription 
enhancing effect was exerted by construct 12a in MM 
cells. This construct contains DH -9,9.  In the sense 
orientation, the enhancing effect could only be demon- 
strated in Mero-82. When transfected into NM cells, both 
12a and 12s had a rather transcription i hibitory effect. 
We have shown that the difference in PDGF B-chain 
mRNA expression between NM and MM cells is mainly 
determined at the transcriptional level. In both cell types, 
the proximal promoter appears to be nucleosome free and 
confers basal evels of transcription. Nuclear factors, which 
may interact with sequences in the proximal promoter, are 
present in both NM and MM cells. However, their concen- 
trations seem to be higher in MM cells. Interaction of 
nuclear factors with an enhancer element at position -9 .9  
kb in MM cells and silencer egions in NM cells in concert 
with factors binding to the 'minimal' promoter determine 
the differential level of PDGF B-chain gene transcription 
in NM and MM cell lines. 
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